Of the 430 people who have participated in the study, 83 percent achieved clinically meaningful weight loss of about 5 percent of their body in the first 12 weeks of treatments. The greatest weight loss (4.1kg) was seen in the first four weeks of treatments. Body mass index was reduced by 2.9 kg/meter squared. Waist circumference was reduced by 6.3 cm on average. The weight loss in the first month of treatment was also associated with rapid improvements in cardiovascular risk factors and reductions in mean diastolic and systolic blood pressure. Reduction of waist circumference decreases insulin resistance; and improves blood sugar, cholesterol levels and blood pressure.
A second presentation of NASOO further confirms that Xenical is successful in maintaining weight loss over a two year period. Xenical is a weight loss drug that works locally in the gut to present dietary fat absorption by around 30 percent. It is well tolerated and unlike appetite suppressants, it does not act on the brain.